166 related articles for article (PubMed ID: 37481022)
1. The Cardiovascular Safety of Five-Alpha-Reductase Inhibitors Among Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
Ayele HT; Reynier P; Azoulay L; Platt RW; Benayoun S; Filion KB
Am J Med; 2023 Oct; 136(10):1000-1010.e7. PubMed ID: 37481022
[TBL] [Abstract][Full Text] [Related]
2. 5-α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population-based cohort study.
Ayele HT; Douros A; Filion KB
Br J Clin Pharmacol; 2022 Aug; 88(8):3771-3781. PubMed ID: 35301747
[TBL] [Abstract][Full Text] [Related]
3. Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study.
Ayele HT; Reynier P; Azoulay L; Platt RW; Cabaussel J; Benayoun S; Filion KB
World J Urol; 2021 Jun; 39(6):2019-2028. PubMed ID: 32909173
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia.
Zhang J; Latour CD; Olawore O; Pate V; Friedlander DF; Stürmer T; Jonsson Funk M; Jensen BC
JAMA Netw Open; 2023 Nov; 6(11):e2343299. PubMed ID: 37962887
[TBL] [Abstract][Full Text] [Related]
5. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Nickel JC; Jick SS
Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study.
Lusty A; Siemens DR; Tohidi M; Whitehead M; Tranmer J; Nickel JC
J Urol; 2021 May; 205(5):1430-1437. PubMed ID: 33616451
[TBL] [Abstract][Full Text] [Related]
7. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
8. 5α-Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
Doherty N; Cardwell CR; Murchie P; Hill C; Azoulay L; Hicks B
Cancer Epidemiol Biomarkers Prev; 2023 Mar; 32(3):428-434. PubMed ID: 36634196
[TBL] [Abstract][Full Text] [Related]
9. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.
Hsieh TF; Yang YW; Lee SS; Lin TH; Liu HH; Tsai TH; Chen CC; Huang YS; Lee CC
PLoS One; 2015; 10(3):e0119694. PubMed ID: 25803433
[TBL] [Abstract][Full Text] [Related]
10. The Cardiovascular Safety of Dutasteride.
Skeldon SC; Macdonald EM; Law MR; Huang A; Paterson JM; Mamdani MM; Juurlink D
J Urol; 2017 May; 197(5):1309-1314. PubMed ID: 27866006
[TBL] [Abstract][Full Text] [Related]
11. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer.
Robinson D; Garmo H; Holmberg L; Stattin P
Cancer Causes Control; 2015 Sep; 26(9):1289-97. PubMed ID: 26109464
[TBL] [Abstract][Full Text] [Related]
12. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.
Shih HJ; Huang CJ; Lin JA; Kao MC; Fan YC; Tsai PS
Prostate; 2018 Feb; 78(2):113-120. PubMed ID: 29119583
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men.
Chang J; Choi S; Kim K; Park SM
J Clin Med; 2019 May; 8(5):. PubMed ID: 31121994
[TBL] [Abstract][Full Text] [Related]
14. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
15. Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
Bengtsen MB; Heide-Jørgensen U; Borre M; Nørgaard M
Prostate; 2023 Jul; 83(10):980-989. PubMed ID: 37057816
[TBL] [Abstract][Full Text] [Related]
16. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
17. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
18. Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia.
Souverein PC; Herings RM; Man in 't Veld AJ; de la Rosette JJ; Farmer RD; Leufkens HG
Eur Urol; 2002 Sep; 42(3):254-61. PubMed ID: 12234510
[TBL] [Abstract][Full Text] [Related]
19. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ
Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480
[TBL] [Abstract][Full Text] [Related]
20. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
